
iBio
Using artificial intelligence to efficiently and consistently delivers antibody candidates against difficult targets.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
* | N/A | $6.2m | Post IPO Equity |
Total Funding | 000k |

USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 45 % | 1 % | - | - | 48 % | (20 %) | - |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (1306 %) | (1918 %) | - | (6676 %) | - | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (979 %) | (2111 %) | - | (11070 %) | (5131 %) | (6749 %) | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 421 % | 744 % | - | 2304 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
iBio, Inc. is a biotechnology company leveraging artificial intelligence and computational biology to create next-generation antibody therapeutics. The company's primary focus is on developing medicines for cardiometabolic diseases, obesity, and difficult-to-treat cancers. It has shifted from a contract manufacturing model to concentrating on its proprietary drug discovery pipeline. The core of its operation is an antibody discovery platform that uses machine learning and 3D modeling to identify promising drug targets and design precision antibodies. This integrated technology stack aims to improve the safety and effectiveness of treatments while reducing development timelines.
Founded in 2008 as iBioPharma, Inc., through a merger involving assets from Integrated BioPharma, the company initially centered on its plant-based FastPharming® System for biologics production. A significant strategic pivot moved the company away from contract development and manufacturing services (CDMO) to prioritize its own therapeutic pipeline, particularly in immuno-oncology and cardiometabolic diseases. The company is publicly traded on the NYSE American under the ticker IBIO and is headquartered in San Diego, California. Leadership includes William D. (Chip) Clark as Chairman and Dr. Martin Brenner as CEO and Chief Scientific Officer.
iBio’s business strategy revolves around advancing its preclinical pipeline and forming strategic collaborations. The company’s technology portfolio includes several key components: an AI-driven Epitope Engineering Engine, a proprietary human antibody library, the StableHu™ antibody optimizer, the EngageTx™ T-cell engager panel, and the ShieldTx® antibody masking technology. These tools are applied to develop candidates like IBIO-101 for solid tumors and new treatments for obesity that aim to preserve muscle mass. Revenue has recently been modest, reflecting the company's transition to an R&D-focused model with significant investment in research activities.
Keywords: antibody discovery, artificial intelligence, biotechnology, immuno-oncology, cardiometabolic disease, biopharmaceuticals, drug development, precision medicine, therapeutic pipeline, epitope engineering
Tech stack
Investments by iBio
Edit